Filing Flows › Gyre Therapeutics (GYRE) › Capital expenditures
Gyre Therapeutics (GYRE) capital expenditures by quarter
Gyre Therapeutics' capital expenditures were $178K in Q1 2026 (first quarter 2026), -73% from Q3 2025. Over the last 3 quarters it ranged from $178K (Q1 2026) to $668K (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $178K | -73% | — |
| Q3 2025 | $668K | +161% | — |
| Q2 2025 | $256K | — | — |
Q1 2026 at a glance
Gyre Therapeutics, Q1 2026: revenue $22.5M (+2% year over year), operating margin -41.5%, net loss $9.9M, operating cash flow $3.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Gyre Therapeutics' capital expenditures?
Gyre Therapeutics' capital expenditures were $178K in Q1 2026 (first quarter 2026), -73% from Q3 2025.
How has Gyre Therapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $178K (Q1 2026) to $668K (Q3 2025).